Host Dr. Timothy Cripe and co-Host Nilay Shah interview Dr. Sajid Qureshi, a professor of Pediatric Oncology at the Tata Memorial Center, Mumbai, India. Dr. Qureshi is an Executive Committee Member of the International Society of Pediatric Surgical Oncology (IPSO). In this episode Dr. Qureshi provides a fascinating, first-hand glimpse into the successes and challenges of delivering quality care to larger, as well as remote, pediatric cancer populations. The episode concludes with Dr. Qureshi's thoughts on how international research collaboration could provide access to relapsed children worldwide.
Entries Tagged as 'pediatric cancer'
October 17th, 2016 · Comments
October 17th, 2016 · Comments
TWiPO Host Dr. Timothy Cripe, with co-hosts Dr. Nilay Shah and Dr. Bhuvana Setty welcome Dr. Damon Reed, Director of the Adolescent and Young Adult Program at Moffitt Cancer Center and Leader of the Pediatric Cancer Foundation's pediatric phase I consortium, the Sunshine Project. Dr. Reed shares his view points on how we can improve and accelerate the current trajectory with regard to pediatric therapy development.
Tags: families · cancer risk · cancer · children · pediatric cancer · childhood cancer · drug development · neuroblastoma · medulloblastoma · sarcoma · research · brain tumor · immunotherapy · clinical trials · Advancement in Cancer Research
October 6th, 2016 · Comments
TWIPO hosts Dr. Timothy Cripe and Dr. Nilay Shah (Nationwide Children's Hospital) along with guest host Dr. Ryan Roberts (Nationwide Children's Hospital), interview Dr. Elizabeth Lawlor who is a Professor of Pediatric Oncology at University of Michigan and the Director of the Cancer Biology Training Program at University of Michigan Health System. Dr. Lawlor, a Ewing Sarcoma specialist, discusses new approaches to the cellular eco-system of tumors and provides commentary on the growing landscape for women in science.
September 6th, 2016 · Comments
On today's podcast, TWIPO host Dr. Timothy Cripe (Nationwide Children’s Hospital) and co-host Dr. Ryan Roberts (Nationwide Children’s Hospital) interview Dr. Mark Hatley (St. Jude Children's Research Hospital). Dr. Hatley discusses how he got into the field of Biological Chemistry in Oncology. Also Dr. Hatley gives an indepth explaination about his research in G-Proteins.
Tags: cancer · children · pediatric cancer · childhood cancer · drug development · neuroblastoma · medulloblastoma · research · brain tumor · immunotherapy · clinical trials · Advancement in Cancer Research
June 3rd, 2016 · Comments
On this episode of TWiPO podcast Dr. Timothy Cripe (Nationwide Children’s Hospital) and co-host, Dr. Nilay Shah (Nationwide Children’s Hospital) and Dr. Keri A. Streby (Nationwide Children's Hospital) interview Dr. Chrystal Louis (Assistant Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine.) Dr. Louis talks to the hosts about her role in both the academic and industry side of oncology.
June 3rd, 2016 · Comments
On today's TWiPO Podcast host Dr. Timothy Cripe (Nationwide Children’s Hospital) and co-host, Dr. Nilay Shah (Nationwide Children’s Hospital) interview Dr. Kim Kramer (Pediatric Oncologist of Memorial Sloan Kettering.) In this interview they discuss a new cutting edge therapy for treating brain tumors, which involves targeting the tumor intravenously just like any other tumor.
April 13th, 2016 · Comments
On today's podcast TWiPO host Dr. Timothy Cripe (Nationwide Children’s Hospital) and co-hosts, Dr. Nilay Shah (Nationwide Children’s Hospital) and Dr. Robyn Dennis (Nationwide Children’s Hospital) Interview Dr. Linda McAllister-Lucas (Chief of Service, Hematology/Oncology of Children's Hospital of Pittsburgh, Associate Professor of Pediatrics, University of Pittsburgh School of Medicine. In their discussion Dr. McAllister-Lucas talks about her research on MALT1 Lymphoma and how this research could advance the field of oncology
December 9th, 2015 · Comments
On this TWiPO episode hosts, Dr. Timothy Cripe and Dr. Nilay Shah (Nationwide Children’s Hospital) interview Dr. James Geller (Medical Director at Kidney and Liver Tumors Program, Co-Medical Director at Retinoblastoma Program, Associate Director at Global Cancer Programs, Associate Professor at UC Department of Pediatrics.) Dr. James Geller was one of the original TWiPO members back in 2010. Today Dr. Geller talks about the battle to get access to potential drugs (Ex. Lorvotuzumab [IMGN901]) that can be beneficial to treating pediatric cancers.
November 2nd, 2015 · Comments
This week in pediatric oncology TWiPO hosts Dr. Timothy Cripe, Robyn Dennis, MD, Dr. Nilay Shah interview Dr. Gregory Armstrong (Associate Professor in the Department of pediatrics at the University of Tennessee health science center, Associate member of in the department of epidemiology in cancer control in Saint Jude's Children's Research Hospital, Director of CNS tumor after completion of therapy clinic at Saint Jude). Dr. Armstrong and hosts discuss the Childhood Cancer Survival Study (CCSS) and the advancements we have made in the field of oncology. Along with problems that they are working to solve.
May 8th, 2015 · Comments
In this most recent TWiPO podcast hosted by Dr. Timothy Cripe (Nationwide Children’s Hospital), he interviews Dr. Jonathan Finlay (Program Director of Neuro-Oncology at Nationwide Children’s Hospital) about sparked in research interest in brain tumors. One of Dr. Finlay’s mentors, helped launch a new treatment, which was able to rescue a proportion of newly diagnosed children who failed conventional chemotherapy, radiation, and surgery. That novel treatment is now a growing method of treating medulloblastoma.
April 20th, 2015 · Comments
TWiPO host Dr. Timothy Cripe (Nationwide Children’s Hospital) and TWiPO co-host Dr. Nilay Shah (Nationwide Children’s Hospital) interview Robin Norris, MD, who is a pediatric oncologist and the Director of the Pediatric Developmental Therapeutics Program, Division of Pediatric Hematology and Oncology, at University Hospitals Rainbow Babies & Children's Hospital. Dr. Norris discusses the struggles that adolescents and young adult with cancer face and discusses her involvement in creating an antibody against TEM-1 in order to stop the metastasis of tumors.
March 11th, 2014 · Comments
March 11, 2014
New York, NY -- This Week in Pediatric Oncology (TWiPO), the first podcast focusing on pediatric cancer research, announced that John Goldberg, MD, from The Sylvester Comprehensive Cancer Center at the University of Miami, is a featured guest on its most recent episode. In this episode, Dr. Golberg talks about the challenges of phase I pediatric cancer clinical trials with hosts Dr. Tim Cripe (Nationwide Children's Hospital), Dr. Robyn Dennis (Nationwide Children's Hospital), and Mark Ranalli, MD (Nationwide Children's Hospital).
Dr. Goldberg is an Assistant Professor of Pediatrics and the Director of the Pediatric Oncology Early Phase Clinical Trials Program at The Sylvester Comprehensive Cancer Center, the University of Miami.
February 10th, 2014 · Comments
August 05, 2011
Host Dr. Tim Cripe and co-host Maureen O’Brien discuss recent papers on immunotherapy and DNA sequencing studies revealing new potential targets in acute lymphoblastic leukemia (ALL).
1:45 min. Results on use of BiTE antibody (Bi-specific T-cell engaging) blinatumomab in adults with lymphoma and leukemia:
Exp Cell Res. 2011 May 15;317(9):1255-60. Epub 2011 Mar 16. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
J Clin Oncol. 2011 Jun 20;29(18):2493-8. Epub 2011 May 16. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
Use of blinatumomab in pediatrics was recently reported in Germany, and an international phase I/II trial for pediatrics is due to begin accruing this year.
Leukemia. 2011 Jan;25(1):181-4. Epub 2010 Oct 14. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia.
23:00 min. Recent findings from the TARGET Initiative (Therapeutically Applicable Research to Generate Effective Treatments) http://target.cancer.gov/
Through NIH's TARGET initiative, scientists sequenced 120 candidate genes in 187 high-risk childhood B-precursor acute lymphoblastic leukemias (HR B-ALL) and normal tissues and combined the results with data from previous studies using microarry and gene copy number studies. Sorting through this massive amount of information revealed a high frequency of recurrent genetic alterations in several specific cancer signaling pathways. The information appears to be useful to stratify these patients into subcategories, some of whom do much better than others. These data highlight potential new therapeutic targets in certain subsets of childhood ALL.
Blood. 2010 Dec 2;116(23):4874-84. Epub 2010 Aug 10. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome
Blood. 2011 Jun 16. [Epub ahead of print] Key pathways are frequently mutated in high risk childhood acute lymphoblastic leukemia: a report from theChildren's Oncology Group
Please send all questions or comments to email@example.com